Update on biological therapeutics for Asthma

Marisha L. Cook, Bruce S. Bochner

Research output: Contribution to journalReview article

Abstract

Asthma poses a significant burden on patients, families, health care providers, and the medical system. While efforts to standardize care through guidelines have expanded, difficulty in managing severe asthma has encouraged research about its pathobiology and treatment options. Novel biologic therapeutics are being developed for the treatment of asthma and are of potential use for severe refractory asthma, especially where the increased cost of such agents is more likely justified. This review will summarize currently approved (omalizumab) and investigational biologic agents for asthma, such as antibodies, soluble receptors, and other protein-based antagonists, and highlight recent published data on efficacy and safety of these therapies in humans. As these newer agents with highly targeted pharmacology are tested in asthma, we are also poised to learn more about the role of cytokines and other molecules in the pathophysiology of asthma.

Original languageEnglish (US)
Pages (from-to)188-194
Number of pages7
JournalWorld Allergy Organization Journal
Volume3
Issue number6
DOIs
StatePublished - Jun 2010

Keywords

  • Asthma
  • Biologic therapies
  • Cytokines
  • Monoclonal antibodies

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Update on biological therapeutics for Asthma'. Together they form a unique fingerprint.

  • Cite this